

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

Batch 35

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No equality issues have been identified.
--

During consultation it was suggested that a subgroup of ‘very elderly’ people (defined by consultees at the scoping workshop as people over about 80 years) should be specified in the scope. Attendees at the scoping workshop noted that there may be little evidence on the effectiveness of edoxaban tosylate in this subgroup. Attendees also advised that factors other than age (such as fitness) can also guide the choice of treatment. During the workshop the technical team explained that, to avoid discrimination, NICE prefers not to make recommendations based solely on age unless there is compelling clinical evidence to support that recommendation. Attendees agreed it was not necessary to consider a subgroup defined by age.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Janet Robertson

Date: 16/09/2014